ALNY FY 2013 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

FY 2013 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$47M-29.3% YoY

Gross Profit

$47M100.0% margin

Operating Income

-$93M-197.0% margin

Net Income

-$89M-189.2% margin

EPS (Diluted)

$-1.45

Cash Flow

Operating Cash Flow

-$69M

Free Cash Flow

-$73M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$421M

Total Liabilities

$150M

Stockholders' Equity

$270M

Cash & Equivalents

$53M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$47M	$67M	-29.3%
Gross Profit	$47M	$67M	-29.3%
Operating Income	-$93M	-$129M	+28.2%
Net Income	-$89M	-$106M	+15.8%